Cargando…

Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes

Medication adherence profoundly affects blood glucose management in patients with type 2 diabetes. Measures to contain the COVID-19 pandemic have affected disease management and medication adherence, owing to limited access to healthcare facilities. This study aimed to examine the impact of the COVI...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Ruth, Chong, Chun Wie, Loganadan, Navin Kumar, Hussein, Zanariah, Adam, Noor Lita, Lee, Shaun Wen Huey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461747/
https://www.ncbi.nlm.nih.gov/pubmed/37644964
http://dx.doi.org/10.2147/PPA.S420545
_version_ 1785097906153324544
author Sim, Ruth
Chong, Chun Wie
Loganadan, Navin Kumar
Hussein, Zanariah
Adam, Noor Lita
Lee, Shaun Wen Huey
author_facet Sim, Ruth
Chong, Chun Wie
Loganadan, Navin Kumar
Hussein, Zanariah
Adam, Noor Lita
Lee, Shaun Wen Huey
author_sort Sim, Ruth
collection PubMed
description Medication adherence profoundly affects blood glucose management in patients with type 2 diabetes. Measures to contain the COVID-19 pandemic have affected disease management and medication adherence, owing to limited access to healthcare facilities. This study aimed to examine the impact of the COVID-19 lockdown on adherence to glucose-lowering and lipid-lowering therapies (statins), and glycemic, weight, and systolic blood pressure control measures. A retrospective chart review was conducted one year pre- and post- March 18, 2020, for patients receiving glucose-lowering medications and lipid-lowering therapies (statins) in two major public hospitals in Malaysia. We compared the proportion of days covered by medication, HbA1c level, weight, and systolic blood pressure (SBP) values pre- and after the index date. A total of 1985 patients were included in this study. The adherence rate significantly increased for metformin, sulfonylureas dipeptidyl peptidase 4 inhibitors (DPP4i) and statin after the index date (metformin (PDC: 0.985 vs 0.978, p < 0.001), sulfonylureas (PDC: 0.988 vs 0.979, p < 0.01), DPP4i (PDC: 0.987 vs 0.98, p < 0.001), and statins (PDC: 0.983 vs 0.978, p < 0.05)). HbA1c levels were significantly reduced after the index follow-up (Mean difference: −0.43%, p < 0.001), while there was a 2.5 mmHg (p = 0.03) significant increase in SBP post-index follow-up. No significant changes in weight were observed during the post-index follow-up period. In this study, we observed better medication adherence and glycemic control among patients during the lockdown, but not for weight and systolic blood pressure control.
format Online
Article
Text
id pubmed-10461747
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104617472023-08-29 Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes Sim, Ruth Chong, Chun Wie Loganadan, Navin Kumar Hussein, Zanariah Adam, Noor Lita Lee, Shaun Wen Huey Patient Prefer Adherence Short Report Medication adherence profoundly affects blood glucose management in patients with type 2 diabetes. Measures to contain the COVID-19 pandemic have affected disease management and medication adherence, owing to limited access to healthcare facilities. This study aimed to examine the impact of the COVID-19 lockdown on adherence to glucose-lowering and lipid-lowering therapies (statins), and glycemic, weight, and systolic blood pressure control measures. A retrospective chart review was conducted one year pre- and post- March 18, 2020, for patients receiving glucose-lowering medications and lipid-lowering therapies (statins) in two major public hospitals in Malaysia. We compared the proportion of days covered by medication, HbA1c level, weight, and systolic blood pressure (SBP) values pre- and after the index date. A total of 1985 patients were included in this study. The adherence rate significantly increased for metformin, sulfonylureas dipeptidyl peptidase 4 inhibitors (DPP4i) and statin after the index date (metformin (PDC: 0.985 vs 0.978, p < 0.001), sulfonylureas (PDC: 0.988 vs 0.979, p < 0.01), DPP4i (PDC: 0.987 vs 0.98, p < 0.001), and statins (PDC: 0.983 vs 0.978, p < 0.05)). HbA1c levels were significantly reduced after the index follow-up (Mean difference: −0.43%, p < 0.001), while there was a 2.5 mmHg (p = 0.03) significant increase in SBP post-index follow-up. No significant changes in weight were observed during the post-index follow-up period. In this study, we observed better medication adherence and glycemic control among patients during the lockdown, but not for weight and systolic blood pressure control. Dove 2023-08-24 /pmc/articles/PMC10461747/ /pubmed/37644964 http://dx.doi.org/10.2147/PPA.S420545 Text en © 2023 Sim et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Short Report
Sim, Ruth
Chong, Chun Wie
Loganadan, Navin Kumar
Hussein, Zanariah
Adam, Noor Lita
Lee, Shaun Wen Huey
Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title_full Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title_fullStr Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title_full_unstemmed Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title_short Impact of COVID-19 Lockdown on Glycemic, Weight, Blood Pressure Control and Medication Adherence in Patients with Type 2 Diabetes
title_sort impact of covid-19 lockdown on glycemic, weight, blood pressure control and medication adherence in patients with type 2 diabetes
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461747/
https://www.ncbi.nlm.nih.gov/pubmed/37644964
http://dx.doi.org/10.2147/PPA.S420545
work_keys_str_mv AT simruth impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes
AT chongchunwie impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes
AT loganadannavinkumar impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes
AT husseinzanariah impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes
AT adamnoorlita impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes
AT leeshaunwenhuey impactofcovid19lockdownonglycemicweightbloodpressurecontrolandmedicationadherenceinpatientswithtype2diabetes